Results 71 to 80 of about 27,758 (263)

Therapeutic potential of targeting MYCN

Medicine, 2020
Neuroblastoma (NB) with MYCN amplification has a poor prognosis and high mortality. The potential molecular biological relationship between clinical features and MYCN amplification should be explored.NB patients were examined by fluorescence in situ hybridization (FISH) for MYCN amplification in the tumor mass or bone marrow samples to determine ...
Huang, Can, Jiang, Shayi, Yang, Jingwei, Liao, Xuelian, Li, Yanhua, Li, Shanshan   +5 more
openaire   +2 more sources

PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status [PDF]

Advanced Pharmaceutical Bulletin
Purpose: The HLF and HuH-6 cell lines represent hepatocellular carcinoma (HCC) with different characteristics in chromosome content that may give different drug responses. Here, PGV-1 was intended to challenge the growth-suppressing effect on HLF and HuH-
Nadzifa Nugraheni, Ummi Maryam Zulfin, Beni Lestari, Novia Permata Hapsari, Muthi Ikawati, Rohmad Yudi Utomo, Yusuke Suenaga, Yoshitaka Hippo, Edy Meiyanto   +8 more
doaj   +1 more source

The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma

Science Advances
Pediatric cancers are frequently driven by genomic alterations that result in aberrant transcription factor activity. Here, we used functional genomic screens to identify multiple genes within the transcriptional coactivator Spt-Ada-Gcn5 ...
Clare F. Malone, Nathaniel W. Mabe, Alexandra B. Forman, G. Alexe, Kathleen L. Engel, Ying-Jiun C. Chen, Melinda Soeung, S. Salhotra, A. Basanthakumar, Bin Liu, Sharon Y. R. Dent, K. Stegmaier   +11 more
semanticscholar   +1 more source

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

EMBO Journal, 2021
High‐risk neuroblastoma (NB) is responsible for a disproportionate number of childhood deaths due to cancer. One indicator of high‐risk NB is amplification of the neural MYC (MYCN) oncogene, which is currently therapeutically intractable.
Marcus Borenäs, G. Umapathy, Wei-Yun Lai, D. Lind, B. Witek, J. Guan, P. Mendoza-García, T. Masudi, A. Claeys, Tzu-Po Chuang, A. El Wakil, B. Arefin, S. Fransson, J. Koster, Mathias Johansson, Jennie Gaarder, J. Van den Eynden, B. Hallberg, R. Palmer   +18 more
semanticscholar   +1 more source

Inactivation of NONO by Auranofin or RNA Interference Triggers Lethal Oxidative Stress in Neuroblastoma Cells

Frontiers in Bioscience-Landmark
Background: Neuroblastoma (NB), a transcriptionally driven pediatric malignancy, exhibits a remarkable clinical and biological heterogeneity.
Sofya S. Pogodaeva, Olga O. Miletina, Lidia V. Mammadova, Nadezhda V. Antipova, Alexander A. Shtil, Oleg A. Kuchur   +5 more
doaj   +1 more source

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma

Frontiers in Oncology, 2021
A wide range of malignancies presents MYCN amplification (MNA) or dysregulation. MYCN is associated with poor prognosis and its over-expression leads to several dysregulations including metabolic reprogramming, mitochondria alteration, and cancer stem ...
Salvatore Raieli, Daniele Di Renzo, Silvia Lampis, Camilla Amadesi, Luca Montemurro, Andrea Pession, Patrizia Hrelia, Matthias Fischer, Matthias Fischer, Roberto Tonelli   +9 more
doaj   +1 more source

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

Journal of experimental & clinical cancer research : CR, 2022
Neuroblastoma is a deadly childhood cancer, and MYCN-amplified neuroblastoma (MNA-NB) patients have the worst prognoses and are therapy-resistant. While retinoic acid (RA) is beneficial for some neuroblastoma patients, the cause of RA resistance is ...
S. Lampis, S. Raieli, L. Montemurro, Damiano Bartolucci, Camilla Amadesi, Sonia Bortolotti, Silvia Angelucci, A. Scardovi, Giammario Nieddu, Lucia Cerisoli, F. Paganelli, S. Valente, M. Fischer, A. Martelli, G. Pasquinelli, A. Pession, P. Hrelia, R. Tonelli   +17 more
semanticscholar   +1 more source

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

Nature Communications
MYCN oncogene amplification is frequently observed in aggressive childhood neuroblastoma. Using an unbiased large-scale mutagenesis screen in neuroblastoma-prone transgenic mice, we identify a single germline point mutation in the transcriptional ...
J. Murray, E. Valli, G. Milazzo, C. Mayoh, Andrew J. Gifford, J. Fletcher, Cheng-Yuan Xue, Nisitha Jayatilleke, Firoozeh Salehzadeh, Laura D. Gamble, J. Rouaen, Daniel R. Carter, Helen Forgham, E. Sekyere, J. Keating, G. Eden, Sophie Allan, S. Alfred, Frances K. Kusuma, Ashleigh Clark, H. Webber, Amanda J. Russell, Antoine de Weck, B. Kile, Martina Santulli, Piergiuseppe De Rosa, Emmy D. G. Fleuren, W. Gao, Lorna Wilkinson-White, J. Low, J. Mackay, G. M. Marshall, D. Hilton, F. Giorgi, Jan Koster, G. Perini, M. Haber, M. Norris   +37 more
semanticscholar   +1 more source

There's a Time and a Place for MYCN [PDF]

Cancer Cell, 2012
Brain tumors display extensive diversity. In this issue of Cancer Cell, Swartling et al. provide evidence that the temporal and spatial transcriptional programs in neural stem cells underlie a diverse response to the MYCN oncogene, potentially contributing to cancer diversity.
Phoenix, Timothy N., Gilbertson, Richard J.   +1 more
openaire   +2 more sources

Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma

Frontiers in Genetics, 2019
As a transcription factor, MYCN regulates myriad target genes including the histone chaperone FACT. Moreover, FACT and MYCN expression form a forward feedback loop in neuroblastoma.
Xinjie Hu, Weisheng Zheng, Qianshu Zhu, Liang Gu, Yanhua Du, Zhe Han, Xiaobai Zhang, Daniel R. Carter, Daniel R. Carter, Daniel R. Carter, Belamy B. Cheung, Belamy B. Cheung, Andong Qiu, Andong Qiu, Cizhong Jiang, Cizhong Jiang   +15 more
doaj   +1 more source